These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1566 related items for PubMed ID: 19135415

  • 21. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.
    Celio L, Frustaci S, Denaro A, Buonadonna A, Ardizzoia A, Piazza E, Fabi A, Capobianco AM, Isa L, Cavanna L, Bertolini A, Bichisao E, Bajetta E, Italian Trials in Medical Oncology Group.
    Support Care Cancer; 2011 Aug; 19(8):1217-25. PubMed ID: 20574663
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
    Billio A, Morello E, Clarke MJ.
    Cochrane Database Syst Rev; 2010 Jan 20; (1):CD006272. PubMed ID: 20091591
    [Abstract] [Full Text] [Related]

  • 24. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
    Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M.
    Ann Oncol; 2003 Oct 20; 14(10):1570-7. PubMed ID: 14504060
    [Abstract] [Full Text] [Related]

  • 25. Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.
    Kubota K, Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T.
    Support Care Cancer; 2016 Sep 20; 24(9):4025-33. PubMed ID: 27129842
    [Abstract] [Full Text] [Related]

  • 26. Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study.
    Kitayama H, Tsuji Y, Sugiyama J, Doi A, Kondo T, Hirayama M.
    Int J Clin Oncol; 2015 Dec 20; 20(6):1051-6. PubMed ID: 25822106
    [Abstract] [Full Text] [Related]

  • 27. Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials.
    Celio L, Agustoni F, Ricchini F, Dotti K, Niger M, Braud FD.
    Future Oncol; 2013 Oct 20; 9(10):1451-8. PubMed ID: 24106896
    [Abstract] [Full Text] [Related]

  • 28. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
    Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Thorn MD, Cox D.
    Support Care Cancer; 2014 Feb 20; 22(2):469-77. PubMed ID: 24141698
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY.
    Intern Med J; 2013 Jan 20; 43(1):73-6. PubMed ID: 22141732
    [Abstract] [Full Text] [Related]

  • 31. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
    Kim KI, Lee DE, Cho I, Yoon JH, Yoon SS, Lee HS, Oh JM.
    Ann Pharmacother; 2012 Dec 20; 46(12):1637-44. PubMed ID: 23170032
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide.
    Matsumoto K, Takahashi M, Sato K, Osaki A, Takano T, Naito Y, Matsuura K, Aogi K, Fujiwara K, Tamura K, Baba M, Tokunaga S, Hirano G, Imoto S, Miyazaki C, Yanagihara K, Imamura CK, Chiba Y, Saeki T.
    Cancer Med; 2020 May 20; 9(10):3319-3327. PubMed ID: 32168551
    [Abstract] [Full Text] [Related]

  • 34. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
    Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A.
    Ann Oncol; 2006 Sep 20; 17(9):1441-9. PubMed ID: 16766588
    [Abstract] [Full Text] [Related]

  • 35. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ, Tzeng WF, Wang WS, Yen CC, Fan FS, Liu JH, Chen PM.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct 20; 63(10):729-36. PubMed ID: 11076429
    [Abstract] [Full Text] [Related]

  • 36. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
    Kitamura H, Takahashi A, Hotta H, Kato R, Kunishima Y, Takei F, Horita H, Masumori N, Sapporo Medical University Urologic Oncology Consortium.
    Int J Urol; 2015 Oct 20; 22(10):911-4. PubMed ID: 26087891
    [Abstract] [Full Text] [Related]

  • 37. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
    Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM.
    Lancet Oncol; 2015 Sep 20; 16(9):1079-1089. PubMed ID: 26272769
    [Abstract] [Full Text] [Related]

  • 38. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C.
    Cancer J Sci Am; 1998 Sep 20; 4(1):52-8. PubMed ID: 9467047
    [Abstract] [Full Text] [Related]

  • 39. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
    Aapro M, Fabi A, Nolè F, Medici M, Steger G, Bachmann C, Roncoroni S, Roila F.
    Ann Oncol; 2010 May 20; 21(5):1083-8. PubMed ID: 20080830
    [Abstract] [Full Text] [Related]

  • 40. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
    Navari RM.
    Future Oncol; 2010 Jul 20; 6(7):1073-84. PubMed ID: 20624119
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 79.